Showing 7061-7070 of 8077 results for "".
- Business News: Candela Acquires Ellipsehttps://practicaldermatology.com/news/business-news-candela-acquires-ellipse/2457616/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Mayo Clinic Doctors Receive Stand Up to Cancer Catalyst Award for Melanoma Researchhttps://practicaldermatology.com/news/mayo-clinic-doctors-receive-stand-up-to-cancer-catalyst-award-for-melanoma-research/2457617/Mayo Clinic immunologist and medical oncologist Matthew Block, M.D., Ph.D. and surgeon Tina Hieken, M.D., received a
- New Skinder App May Help Med Students Spot Skin Cancerhttps://practicaldermatology.com/news/new-skinder-app-may-help-med-students-spot-skin-cancer/2457627/Skinder, a dermatologist-developed app, may help medical students learn to spot skin cancer. Skinder works like the matchmaking app Tinder. But instead of considering pictures of potential dates, swiping right if they’re attractive or left if they’re not, users consider high-r
- Compulink Launches Advantage SMART Practice Suite of AI Solutionshttps://practicaldermatology.com/news/compulink-launches-advantage-smart-practice-suite-of-ai-solutions/2457629/Compulink Healthcare Solutions rolled out new artificial intelligence (AI)-enabled features in a release its calling Advantage SMART Practice. Advantage uses AI technology and real-time data from the clinic to completely automate tasks such as billing, along with eliminating steps to improve pati
- FDA Accepts Ortho Derm's Resubmission of NDA for Duobrii Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-ortho-derms-resubmission-of-nda-for-duobrii-lotion-for-plaque-psoriasis/2457630/The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application (NDA) for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis. The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of Feb. 15,
- Novel Epigenetic Mechanism May Cause Drug Resistance in Melanomahttps://practicaldermatology.com/news/novel-epigenetic-mechanism-may-cause-drug-resistance-in-melanoma/2457634/New research sheds light on epigenetic reason for drug resistance in melanoma, and identifies potential therapies that may prevent such resistance, according to a paper in Nature Communications. Mount Sinai researchers identified a novel e
- FDA Nod for Ortho Derm's Acne Lotion Altrenohttps://practicaldermatology.com/news/fda-nod-for-ortho-derms-acne-lotion-altreno/2457635/The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Ortho Dermatologic’s Altreno (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in patients aged 9 and up. Altreno is expected to be
- Researchers Identify Cause of Aggressive SCCs in Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/researchers-identify-cause-of-aggressive-sccs-in-recessive-dystrophic-epidermolysis-bullosa/2457636/Immune system-related enzymes contribute significantly to the development of aggressive and fatal squamous cell carcinomas early in the life of individuals with recessive dystrophic epidermolysis bullosa (RDEB), an international team of scientists led by researchers at the Sidney Kimmel Canc
- Report: Psoriasis in America in 2018https://practicaldermatology.com/news/report-psoriasis-in-america-in-2018/2457640/Recently released psoriasis survey results reveal that only 10 percent of patients feel their condition is under control with their current treatment plans; meanwhile, their symptoms—and the mental emotional effects of those symptoms—are overwhelming. The survey, "
- Ortho Dermatologics Resubmits NDA for Duobrii Lotionhttps://practicaldermatology.com/news/ortho-dermatologics-resubmits-nda-for-duobrii-lotion/2457646/Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; IDP-118) lotion in the treatment of p